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A B S T R A C T
Background: In 2012, the ﬁrst Nigerian Hepatitis B Virus (HBV) immune escape mutant (IEM) case was
detected in a pregnant woman in southwestern Nigeria. Consequently, this study was designed to
investigate the presence and possible circulation of IEMs amongst asymptomatic community dwellers in
southwestern Nigeria.
Methods: Blood specimens collected from 438 asymptomatic community dwellers were screened for
HBsAg using ELISA technique. Subsequently, the S-gene was ampliﬁed in HBsAg positive samples by a
nested PCR protocol, and amplicons sequenced. Isolates were then subtyped by amino acid residues at
positions 122, 127, 134 and 160, and genotyped by phylogenetic analysis.
Results: Of the 31 (7.08%) samples positive for HBsAg, the 408 bp Sgene fragment was successfully
ampliﬁed and sequenced in 27. Samples obtained from 4 patients could not be ampliﬁed due to low
titres. Sequence data from only 15 of the isolates could be analysed further as eight of the remaining
12 had multiple peaks while the rest three showed no similarity to any HBV gene when subjected to
BLAST analysis. Thirteen of the 15 isolates were identiﬁed as genotype E. Eleven of which were subtyped
as ayw4 while the remaining two could not be subtyped due to sR122Q/P substitutions. The last two
isolates that could not be genotyped and subtyped had other mutations in the ‘‘a’’ determinant
associated with IEMs.
Conclusions: This study conﬁrmed presence and circulation of HBV IEM in Nigeria, the country’s
inclusion in the genotype E crescent, and the value of phylogenetic analysis in HBV identiﬁcation.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Globally, it is estimated that about 360 million people are
chronically infected with Hepatitis B Virus (HBV) and over two
billion people have serologic evidence of past or present HBV
infection.1 Consequently, HBV ranks as one of the top 10 viral
infections.2 There is evidence that chronic HBV infection could
result in cirrhosis and accounts for a signiﬁcant number of deathsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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HBV infection could also manifest as acute, self-limiting disease.4
HBV is a member of the genus orthohepadnavirus, family
Hepadnaviridae. The virion has a host derived lipid envelope and a
diameter of 42 nm. Within the envelope, the partially dsDNA,
3.2 kb genome is enclosed in a capsid made up the core (C)
protein. Based on how different their genomes are, eight genotypes
of HBV have been described.5 Genomes that differ by not more
than 8%6 and 4%7 are classiﬁed as belonging to the same genotype
and sub-genotype respectively. The HBV genome has four open
reading frames (ORFs) named X, C, P and S with the S ORF
overprinted on the P ORF in a different reading frame.
The S ORF codes for the HBV surface antigen (HBsAg) which is
the only HBV genome- encoded trans-membrane protein present
in the virion membrane.8,9 HBsAg functions as the virus attach-
ment protein and antibodies elicited against speciﬁc epitopes on it
have neutralizing activity.10 In addition, when expressed in
eukaryotic cells, HBsAg has the capacity to produce the 22 nm
spheres and ﬁlaments that are found in HBV infected individuals
and account for over 80% of the HBsAg in such people.9,11
Initially, these 22 nm spheres and ﬁlaments were puriﬁed from
the serum of HBV infected individuals and used as vaccines.10,12–14
This has however been replaced by recombinant vaccines
produced by expression of HBsAg in eukaryotic cells.15,16
Furthermore, neutralizing antibodies (HBIg) elicited against
speciﬁc epitopes on HBsAg have been produced and are available
as a form of passive immunization.3 The availability of an effective
and safe HBV vaccine has resulted in a global effort to eradicate
HBV. Consequently, in most countries of the world HBV vaccine is
administered to at risk individuals and children at birth.4,17
Cases in which people with immunological correlates of HBV
immunity get re-infected have been described18–21 and this poses
a serious threat to the success of the HBV eradication programme.
Isolates recovered from such cases were coined Immune Escape
Mutants (IEMs).18,22,23 First described in 1990,18 this adaptive
response of HBV to selective pressure has been ascribed to the RNA
phase in its replication cycle and a polymerase that lacks ‘‘proof-
reading’’ ability.24,25 As a result, mutants develop during replica-
tion at almost the same rate as RNA viruses24,25 and the most ﬁt
members of the mutant population can be selected for by anti-HBs
and in other cases, nucleoside/nucleotide analogue classes of
antiviral drugs.26
Though the presence and circulation of IEMs have been
reported globally since 1990,18–21,27 in 2012, the ﬁrst Nigerian
IEM case with mutations in the ‘‘a’’ determinant was detected in a
pregnant woman in southwestern Nigeria.28 Consequently, this
study was designed to investigate the possible circulation of IEMs
in asymptomatic community dwellers in the region. This study
reports the presence and circulation of HBV IEMs in asymptomatic
community dwellers in southwestern Nigeria.
2. Methodology
2.1. Study location and Sample collection
This study was carried out in Ibadan, Oyo State, southwestern
Nigeria. The study was community based and ethical approval for
the study was granted by the Oyo State Ministry of Health (AD3/479/
349). Samples analysed in this study were collected from apparently
healthy community dwellers between July and September,
2013. During every sample collection visit, before sample collection,
consenting participants were educated on HBV infection, its clinical
manifestation, prevalence and control. Subsequently, a question-
naire was administered in a bid to retrieve demographic and other
relevant information. Afterwards, a blood sample was collected
from a total of 438 {median age = 30 years, age range = 1.5 – 87 years(Male = 133; age range = 1.5 – 87 years; Females = 305; age range =
7 – 80 years)} consenting participants.
Using venepuncture, ﬁve millilitres of blood was collected from
each participant and dispensed into anticoagulant-free, appropri-
ately labelled sterile container. Thereafter, the samples were
transported to the laboratory in the Department of Virology,
College of Medicine, University of Ibadan, in cold chain. On arrival
at the laboratory, the blood sample was centrifuged at 500Xg for
ﬁve minutes. The serum was then carefully collected using sterile
disposable pipettes and aliquoted into two appropriately labelled
cryovials per sample. Subsequently, sera from the blood samples
were stored at 20 8C until analysed. Laboratory analysis was
carried out in both the Department of Virology, and the Institute
for Advanced Medical Research and Training, College of Medicine,
University of Ibadan, Ibadan, Nigeria.
2.2. HBsAg ELISA Screening Test
A sandwich enzyme linked immunosorbent assay (ELISA) for
detection of HBsAg (Diagnostic Automation/Cortez Diagnostic,
California, USA) was used to screen all the 438 sera for the presence
of HBsAg. The assay was carried out in accordance with
manufacturer’s instructions. The Emax endpoint ELISA microplate
reader (Molecular Devices, California, USA) was used to determine
the optical density after which the result was interpreted in
accordance with the manufacturer’s instructions.
2.3. DNA extraction and S-gene speciﬁc Polymerase Chain Reaction
(PCR).
This was done as previously described.28,29 Brieﬂy, the QIAGEN
DNA extraction kit (Qiagen, Hilden, Germany) was used for viral
DNA extraction in accordance with the manufacturer’s instruc-
tions. Afterwards, a 408 bp stretch within the S ORF of the HBV
genome was detected using a nested PCR assay. Primers used were
HBV_S1F and HBV_S1R for the ﬁrst round and HBV_SNF and
HBV_SNR for the second round.
Two microlitres of each of the primers (made in 25 mM
concentrations) were added to a 50 mL reaction which also
contained 10 mL of Red load Taq (Jena Bioscience, Jena, Germany),
4 mL of DNA and 32 mL of RNase free water. Veriti Thermalcycler
(Applied Biosystems, California, USA.) was used for thermal cycling
as follows; 94 8C for 3 minutes followed by 45 cycles of 94 8C for
30 seconds, 55 8C for 60 seconds and 70 8C for 40 seconds with
ramp of 40% from 55 8C to 70 8C. This was then followed by 72 8C
for 7 minutes and held at 4 8C till terminated.
Both ﬁrst and second round PCR reaction conditions were the
same except that DNA extract from the sample was used as
template for ﬁrst round while ﬁrst round PCR product was used as
template for second round PCR. All PCR products were resolved on
2% agarose gels stained with ethidium bromide and viewed using a
UV transilluminator.
2.4. Amplicon sequencing
Positive PCR reactions were shipped to Macrogen Inc, Seoul,
South Korea, for amplicon puriﬁcation and BigDye chemistry
sequencing. Sequencing was done using second round PCR
primers.
2.5. Phylogenetic analysis
Determination of HBV serotypes was done using amino acid
residues at positions 122, 127, 134 and 160 of the S-gene.27
Afterwards, partial S-gene sequences generated in this study were
aligned alongside S-gene reference sequences downloaded from
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using the CLUSTAL W program in MEGA 5 software with default
settings.30 Subsequently, using the MEGA 5 software, Kimura-2
parameter model and 1,000 bootstrap replicates, a neighbour-
joining tree was constructed and used to determine the genotypes
of all isolates. In addition, S-gene pairwise distance was estimated
using MEGA 5 software with Kimura-2 parameter model.31
2.6. SimPlot Analysis
SimPlot version 3.532 was used to assess similarity to reference
sequences of sequences that could not be typed using the above
methods. It was also used to assess the probability that such
sequences were of recombinant origin. To ensure recombinant
sequences will be detected, two genotype D/E recombinant
sequences (gnljhbvcdsjAB033559 and gnljhbvcdsjAB048702) were
downloaded from the HBV database (http://hbvdb.ibcp.fr/HBVdb/)
and included in multiple sequence alignment of reference and
query sequences used for this analysis.
Similarity plots were generated using the Kimura (2-parame-
ter) distance model, a window size of 200 bp moving in steps of
20 bp. Subsequently, using the Kimura (2-parameter) distance
model, a neighbour-joining tree model and 100 bootstrap repli-
cates, bootscan analysis was run with a window size of 200 bp
moving in steps of 20 bp in a bid to detect any recombination
event.
2.7. Nucleotide sequence accession numbers
Accession numbers of S-gene sequences retrieved from the HBV
database are indicated in the sequence names on the phylograms.
The S-gene sequences reported in this study have been submitted
to GenBank under ‘‘the accession numbers KP780133 to
KP780147’’.
3. Results
3.1. HBsAg ELISA Screening Test
HBsAg was detected in 31 (7.08%) of the 438 samples screened.
The remaining 407 (92.92%) samples were negative for HBsAg.
HBsAg was detected in samples from subjects within the ages of
18 – 67 years. Among the males, 17 (12.78%) of the 133 samples
collected were positive for HBsAg. This represents 54.84% (17/31)
of the total number of HBsAg positive samples recorded in this
study. Among the females, 14 (4.59%) of the 305 samples collected
were positive for HBsAg. This represents 45.16% (14/31) of the total
number of HBsAg samples detected in this study. (Table 1).Table 1
Age and gender distribution of HBsAg prevalence amongst asymptomatic community 
S/N Age Group
(Years)
MALE FEMALE 
Frequency HBsAg HBsAg Negative Frequenc
Positive (%) 
1 <18 15 0 (0.0%) 15 11 
2 18–27 38 5 (13.16%) 33 142 
3 28–37 28 5 (17.86%) 23 40 
4 38–47 22 3 (13.64%) 19 43 
5 48–57 15 3 (20.00%) 12 45 
6 58–67 7 1 (14.29%) 6 14 
7 >67 8 0 (0.0%) 8 10 
TOTAL 133 17 (12.78%) 116 305 3.2. DNA extraction, S-gene speciﬁc Nested Polymerase Chain
Reaction (nPCR) and Sequence analysis
All the 31 HBsAg positive samples were subjected to DNA
extraction and HBV S-gene speciﬁc nPCR. Only 27 (87.1%) of the
samples yielded the expected 408 bp amplicon. The remaining
four (12.9%) samples yielded no amplicon despite repeated
attempts using varied annealing and extension temperatures.
All the 27 amplicons were sequenced. However, 9 (33.33%)
were not exploitable due to the presence of multiple peaks. The
sequence data of the exploitable 18 isolates were then subjected to
further analysis.
3.3. Phylogenetic analysis
After the forward and reverse sequencing results per isolate
were stitched into contigs, each was subjected to a BLASTn search
on the NCBI BLAST webpage. Fifteen of the isolates showed
signiﬁcant similarity to HBV S-gene. The remaining three isolates
were similar to a human gene and showed no similarity to the HBV
S-gene. Consequently, these three isolates were stepped down
from further analysis.
Using amino acid residues at positions s122, s127, s134 and
s160,27,28 eleven of the 15 isolates were subtyped as ayw4
(Table 2). As a result of substitutions at positions s122 (Table 1,
Figure 1), the remaining four isolates (NGR IBGP 20 C4 HBsAg, NGR
IBGP 73 D6 HBsAg, NGR IBGP 121 E1 HBsAg and NGR IBGP 408 H2
HBsAg) could not be subtyped.
In a bid to genotype the isolates, representative HBV S-gene
sequences of genotypes A – H were downloaded from the HBV
database (http://hbvdb.ibcp.fr/HBVdb/). These reference
sequences alongside HBV S-gene sequences previously described
in the region28were used to construct a phylogram. The phylogram
showed that all the eleven isolates previously subtyped as ayw4
were genotype E. In addition, NGR IBGP 121 E1 HBsAg and NGR
IBGP 408 H2 HBsAg which could not be subtyped because of
sR122Q/P substitutions also belonged to genotype E (Figure 2). In
fact, these two isolates were only 1.42% and 1.7% divergent
(Table 3) from a reference genotype E isolate (AB091255).
The remaining two isolates, NGR IBGP 20 C4 HBsAg and NGR
IBGP 73 D6 HBsAg were recovered from a 30 year old male and an
18 year old female respectively. These isolates did not belong to
genotype E as they were more than 11% divergent from the
reference genotype E sequence (Table 3). The phylogram (Figure 2)
however showed both isolates clustering with an isolate (NGRUC-
12-054 A8 HBsAg) previously described as an Immune Escape
Mutant (IEM).28 Subsequently, isolates NGR IBGP 20 C4 HBsAg and
NGR IBGP 73 D6 HBsAg were shown to be more than 11% divergent
from genotypes A – H, 3.46% divergent from each other, and 3.47%dwellers in Ibadan, Oyo State, Nigeria.
TOTAL
y HBsAg HBsAg Frequency HBsAg Positive HBsAg
Positive (%) Negative (%) Negative
0 (0.0%) 11 26 0 (0.0%) 26
7 (4.93%) 135 180 12 (6.67%) 168
3 (7.50%) 37 68 8 (11.76%) 60
3 (6.98%) 40 65 6 (9.23%) 59
1 (2.22%) 44 60 4 (6.67%) 56
0 (0.0%) 14 21 1 (4.76%) 20
0 (0.0%) 10 18 0 (0.0%) 18
14 (4.59%) 291 438 31 (7.08%) 407
Table 2
Serotype of sequenced HBV isolates
S/N Sample ID Amino acid residues at
positions within the surface
antigen for serotype
determination
Serotype/
Subtype
s122 s127 s134 s160
1 NGR IBGP 20 C4 HBsAg Q L F K Untypable
2 NGR IBGP 22 C5 HBsAg R L F K ayw4
3 NGR IBGP 30 C6 HBsAg R L F K ayw4
4 NGR IBGP 32 C7 HBsAg R L F K ayw4
5 NGR IBGP 34 C8 HBsAg R L F K ayw4
6 NGR IBGP 43 D1 HBsAg R L F K ayw4
7 NGR IBGP 53 D2 HBsAg R L F K ayw4
8 NGR IBGP 71 D5 HBsAg R L F K ayw4
9 NGR IBGP 73 D6 HBsAg Q L F K Untypable
10 NGR IBGP 121 E1 HBsAg Q L F K Untypable
11 NGR IBGP 137 E2 HBsAg R L F K ayw4
12 NGR IBGP 296 G3 HBsAg R L F K ayw4
13 NGR IBGP 393 G8 HBsAg R L F K ayw4
14 NGR IBGP 402 H1 HBsAg R L F K ayw4
15 NGR IBGP 408 H2 HBsAg P L F K Untypable
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12-054 A8 HBsAg) (Table 4). The similarity of isolates NGR IBGP
20 C4 HBsAg and NGR IBGP 73 D6 HBsAg to NGRUC-12-054 A8
HBsAg is further demonstrated in the conservation of almost the
same amino acid substitutions in the three isolates (Figure 1). The
Major Hydrophilic Region (MHR; s122 – s160) of isolate NGR IBGP
20 C4 HBsAg and NGR IBGP 73 D6 HBsAg had the following amino
acid substitutions which they shared with NGRUC-12-054 A8
HBsAg; sR122Q, sC124Y, sA128T, sG130K, sC138Y, sG145K,
sC147Y, sA157T and sG159K (Figure 1). In addition, NGR IBGP
20 C4 HBsAg also had sD144N.
Similarity plots (Figure 3A & B) showed the three isolates to be
very similar to one another but different from the other referenceFigure 1. Alignment of amino acid residues of the ﬁfteen isolates sequenced in this study
interest are isolatesNGRUC-12-054-A8-HBsAg, NGRUC-13-084-B7-HBsAg and NGRUC- sequences, the recombinant sequences inclusive. Furthermore,
bootscan analysis didn’t detect any evidence of these three
sequences being of recombinant origin (Figure 3C) despite being
able to detect reference sequences of recombinant origin as such
(Figure 3D).
4. Discussion
4.1. HBV IEMs
Two (NGR IBGP 20 C4 HBsAg and NGR IBGP 73 D6 HBsAg) of the
HBV isolates described in this study have the sG145K substitution
which alongside the sG145R substitution have been repeatedly
documented and associated with HBV IEMs.18,22,33–35 In fact, the
IEM status of these two isolates was conﬁrmed by the geno2pheno
software (http://hbv.geno2pheno.org/) (data not shown). The
results of this study therefore conﬁrm the ﬁndings of Faleye
et al.,28 that HBV IEMs are present in Ibadan, southwestern,
Nigeria. It further shows that IEM is present in asymptomatic
community dwellers in the region.
In the isolates NGR IBGP 20 C4 HBsAg and NGR IBGP 73 D6
HBsAg, the cysteine residues at positions sC124Y, sC138Y and
sC147Y have been substituted with tyrosine (Figure 1). These
substitutions will abolish the formation of disulphide bonds that
have been predicted to stabilize the double-loop structure of the
HBV MHR.36 The consequent conformational alteration of the MHR
might further enhance the predicted IEM phenotype as previously
suggested.28
The HBV IEMs described in this study share substitutions in
the ‘‘a’’ determinant between themselves and with the HBV IEM
recently described in a pregnant woman in the same geographi-
cal region (Figure 1).28 For instance, between amino acids 122 to
160, these three isolates share nine substitutions together. This
level of conservation conﬁrms the results of the phylogram
(Figure 2) which suggests that these isolates share a common and the seven sequenced in [28] against a reference genotype E strain. Of particular
13-100-C1-HBsAg with mutations in the MHR (s122 to s16.
Figure 2. Phylogenetic relationship of HBV isolates. The phylogram is based on an
alignment of the partial HBsAg sequences. The newly sequenced strains are
highlighted with black circle and triangle. Speciﬁcally, the isolates that could not be
typed using amino acid residues at positions s122, s127, s134 and s160 are
indicated with black triangles. On the other hand, those that were typable by the
amino acid residue algorithm are indicated with black circles. The HBV IEMs
previously described [28] is indicated with a black diamond. The accession numbers
of the strains are indicated in the phylogram. Bootstrap values are indicated if 70%.
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emerged at one point in time. To further buttress the evidence for
circulation is the fact that the 18 year old female from whom NGR
IBGP 73 D6 HBsAg was recovered also had HBcIgM (unpublished
data). This suggests she was sampled within the ﬁrst six months
of infection. The results of this study therefore show that HBV
IEMs are not just present but also circulating in asymptomatic
community dwellers in Ibadan, southwestern, Nigeria. It is not
clear when this isolate emerged and how long it has been in
circulation. However, what is obvious is that none of the studies
done in the region before 2012 ever reported detection of HBV
IEMs with this combination of mutations in the ‘a’ determi-
nant.29,37 To the best of the authors’ knowledge, the only report
from Nigeria, prior to our discovery of this strain in 2012,28
describing mutations in HBV suggestive of immune escape
phenotype,37 found deletions in the pre-S2 region. The HBV IEM
strains described in this study and Faleye et al., 201526 might
therefore be a recent development.
Despite the fact that the IEMs detected in this study and that
are described in Faleye et al.,28 were >11% divergent from all
reference HBV genotypes A – H isolates used in this study and
were were not of recombinant origin (Figure 3), these isolates are
within the 8% genotype threshold6 amidst themselves (Table 4). In
fact, going by the 4% sub-genotype threshold7 they all appear to
belong to the same sub-genotype because NGR IBGP 20 C4 HBsAg
is 3.46% and 3.47% divergent from NGR IBGP 73 D6 HBsAg and
NGRUC-12-054 A8 HBsAg respectively. It has therefore not
escaped our notice that these three isolates might represent
members of a new genotype of HBV that have gone undetected till
recently. However, more studies are required to test the validity of
this hypothesis.
4.2. The Genotype E Crescent
Thirteen of the 15 HBV isolates detected in this study were
identiﬁed as belonging to genotype E, thus further conﬁrming
the inclusion of Nigeria in the genotype E crescent.28,29,37–40 If
only subtyping was done, using amino acids at positions s122,
s127, s134 and s160, for isolate classiﬁcation, two of the thirteen
typed isolates would have remained untypable. Hence, the
ﬁndings of this study emphasize the need to use more than one
algorithm when identifying HBV isolates in a bid to reduce the
occurrence of untypable isolates.28 However, the impact of the
sR122Q/P substitution on the immunological properties and the
consequent subtype of these two isolates remain to be
determined.
4.3. HBV DNA Detection
Of the 31 HBsAg samples detected in this study, the HBV DNA
detection assay produced the expected band size in only 27. The
inability to detect the expected band size in the remaining four
samples might be an indication of low viral load in the samples. In
addition, it might even be suggestive of mutated or recombinant
origin of the isolates in these samples and the resultant inability of
the primers to recognize the target site. Furthermore, the
possibility exists that these four individuals are inactive carriers.4
However, considering that these samples are yet to be fully proﬁled
for all HBV serological markers, the carrier state of these four
individuals is at best speculative. Effort is however ongoing to
better resolve the status of these cases.
There were nine samples whose sequence data were unex-
ploitable due to the presence of multiple peaks. This might be
suggestive of multiple isolates or genotypes in these individuals. In
our experience, focused group discussions with such cases
revealed that a good number were involved in practices that
Table 3
Comparison of reference sequence gnljhbvcdsjAB091255 genotype E to all isolates recovered in this study
S/N ISOLATE ID GENOTYPE E REFERENCE Dist% Siml%
1 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 11.99 88.01
2 NGR IBGP 22 C5 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.99 98.01
3 NGR IBGP 30 C6 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 0.85 99.15
4 NGR IBGP 32 C7 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.70 98.30
5 NGR IBGP 34 C8 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 0.85 99.15
6 NGR IBGP 43 D1 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 2.28 97.72
7 NGR IBGP 53 D2 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.13 98.87
8 NGR IBGP 71 D5 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.13 98.87
9 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 11.95 88.05
10 NGR IBGP 121 E1 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.42 98.58
11 NGR IBGP 137 E2 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 0.85 99.15
12 NGR IBGP 296 G3 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 0.28 99.72
13 NGR IBGP 393 G8 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.42 98.58
14 NGR IBGP 402 H1 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.13 98.87
15 NGR IBGP 408 H2 HBsAg gnljhbvcdsjAB091255 REFERENCE BACKBONE genotype E 1.70 98.30
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intercourse with multiple sexual partners (unpublished).
Three isolates yielded exploitable data that were most similar
to a human gene and totally unrelated to HBsAg (data not shown).
This raises concerns about the nPCR assay used in this study.
Speciﬁcally, the assay should not be used in isolation for HBV
diagnosis, especially in the investigation of ‘‘occult’’ HBV infection.
This is because the detection of the expected band size without
subsequently sequencing the amplicon does not conﬁrm the
presence of HBV DNA.Table 4
Comparison of isolates NGR IBGP 20 C4 HBsAg and NGR IBGP 73 D6 HBsAg to reference
IEM) and each other.
S/N Species 1 Species 2 
1 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB014370 g
2 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB014370 g
3 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB030513 g
4 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB030513 g
5 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB010289 g
6 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB010289 g
7 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB010290 g
8 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB010290 g
9 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB014360 g
10 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB014360 g
11 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB014361 g
12 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB014361 g
13 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB048701 g
14 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB048701 g
15 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB078031 g
16 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB078031 g
17 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB091256 g
18 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB091256 g
19 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB091255 R
20 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB091255 R
21 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB036905 g
22 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB036905 g
23 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB036909 g
24 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB036909 g
25 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB056513 g
26 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB056513 g
27 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB056514 g
28 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB056514 g
29 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB059659 g
30 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB059659 g
31 NGR IBGP 20 C4 HBsAg gnljhbvcdsjAB059660 g
32 NGR IBGP 73 D6 HBsAg gnljhbvcdsjAB059660 g
33 NGR IBGP 20 C4 HBsAg NGRUC-12-054 A8 HBs
34 NGR IBGP 73 D6 HBsAg NGRUC-12-054 A8 HBs
35 NGR IBGP 20 C4 HBsAg NGR IBGP 73 D6 HBsAg4.4. Prevalence of HBsAg
HBsAg prevalence in Nigeria has been estimated to vary
between 2.5% to about 40% depending on the studied popula-
tion.29,41 Consequently, Nigeria is considered to be an HBV
endemic country.29 However, the results of this study show
HBsAg prevalence of 7.08% in asymptomatic community dwellers
in Ibadan southwest Nigeria. This falls within the range deﬁned by
previous studies29,41 and is in perfect agreement with the ﬁndings
of Okonko et al.,.42 sequences from genotypes A to H, NGRUC-12-054 A8 HBsAg (previously described
Dist% Siml%
enotype A 17.30 82.70
enotype A 17.27 82.73
enotype A 17.27 82.73
enotype A 17.23 82.77
enotype B 15.88 84.12
enotype B 15.84 84.16
enotype B 15.88 84.12
enotype B 15.84 84.16
enotype C 19.29 80.71
enotype C 19.24 80.76
enotype C 18.16 81.84
enotype C 18.11 81.89
enotype D 16.75 83.25
enotype D 16.71 83.29
enotype D 17.77 82.23
enotype D 17.73 82.27
enotype E 11.89 88.11
enotype E 11.86 88.14
EFERENCE BACKBONE genotype E 11.89 88.11
EFERENCE BACKBONE genotype E 11.86 88.14
enotype F 18.07 81.93
enotype F 18.03 81.97
enotype F 18.07 81.93
enotype F 18.03 81.97
enotype G 17.73 82.27
enotype G 17.69 82.31
enotype G 17.73 82.27
enotype G 17.69 82.31
enotype H 16.85 83.15
enotype H 18.33 81.67
enotype H 16.85 83.15
enotype H 17.57 82.43
Ag 3.47 96.53
Ag 4.06 95.94
 3.46 96.54
Figure 3. Similarity Plot and Bootscan analysis of the suspected Immune Escape Mutants and reference sequences. Figures 3A and 3B show similarity plots while Figures 3C
and 3D show bootscan analysis results. NGRUC-12-054-A8-HBsAg is the query sequence in Figures 3A and 3C while gnljhbvcdsjAB048701_genotype_D is the query sequence
in Figures 3B and 3D.
T.O.C. Faleye et al. / International Journal of Infectious Diseases 39 (2015) 102–109108Studies have shown that HBsAg prevalence is usually higher in
males than in females.41,42 The ﬁndings of this study are in no wise
different with HBsAg prevalence of 12.78% and 4.59% in males and
females respectively. Reasons for this gender dependent difference
have been suggested elsewhere.41,42
5. Conclusions
The results of this study conﬁrmed that HBV IEM is present in
Ibadan, Southwest Nigeria. Furthermore, it shows for the ﬁrst time
that HBV IEMs are circulating in the region. It also conﬁrms the
inclusion of Nigeria in the genotype E crescent and reafﬁrms the
value of phylogenetic analysis in HBV identiﬁcation. Finally, it
raises concerns about the use of HBV DNA detection in isolation (i.e
without sequencing and sequence analysis) for HBV diagnosis,
because the detection of the expected band size without
conﬁrmation by subsequently sequencing the amplicon might
not conﬁrm the presence of HBV DNA.
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